Neumora Therapeutics, Inc. - 8-K Filing

Neumora Therapeutics reports Q3 2026 net loss of $34.4 million and announces IND submission for NMRA-215 obesity program. (Items: 2.02 Results of Operations and Financial Condition, 9.01 Financial Statements and Exhibits)

SEC EDGAR ·

Tickers: $NMRA

Read the full article at SEC EDGAR

More Regulatory news